Eva Ciruelos
Researcher Next ID · RN-035438
Researcher · Biochemistry, Genetics and Molecular Biology
Research Institute Hospital 12 de Octubre
Madrid, Spain
- Works count
- 695
- Citation count
- 20,161
- H-index
- 55
- i10-index
- 157
Research interests
Publications
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-03261-7
Spatial predictors of immunotherapy response in triple-negative breast cancer
Nature · 2023 · https://doi.org/10.1038/s41586-023-06498-3
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.02.004
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30863-0
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.05.001
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.11.011
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz177
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx308
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1413513
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00373-3
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
New England Journal of Medicine · 2014 · 10.1056/nejmoa1404037
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
New England Journal of Medicine · 2014 · 10.1056/nejmoa1412379
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70080-4
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70130-x
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(09)61964-4
Current projects
No projects listed.